Be among the first to receive PYLARIFY® updates including new imaging locations and reimbursement

Sign up for updates Fields marked * are required.


PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.


  1. FDA clearance letter for aPROMISE. Food and Drug Administration. July 27, 2021.